Download PDF

1. Company Snapshot

1.a. Company Description

Nutriband Inc.develops a portfolio of transdermal pharmaceutical products.The company's lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.


It also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility.Nutriband Inc.has a license agreement with Rambam Med-Tech Ltd.


for the development of the RAMBAM Closed System Transfer Devices.The company was incorporated in 2016 and is headquartered in Orlando, Florida.

Show Full description

1.b. Last Insights on NTRB

Nutriband Inc.'s recent performance was negatively impacted by its Q2 earnings report, which showed a significant loss of $2.12 per share, surpassing the estimated loss of $0.17 per share. Despite achieving record revenue for Q2 2025, up 50.87% year-over-year, the company's progress toward NDA filing for AVERSA Fentanyl was overshadowed by the earnings miss. Additionally, CEO Gareth Sheridan's decision to seek nomination in the Irish Presidential Election, leading to his temporary departure, may have added uncertainty. However, the company secured $5,306,000 in gross proceeds from warrant exercises at $6.43. (Source: Zacks Consensus Estimate)

1.c. Company Highlights

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Card image cap

Head to Head Review: Nutriband (NASDAQ:NTRB) vs. Quoin Pharmaceuticals (NASDAQ:QNRX)

Dec -04

Source: defenseworld.net

Card image cap

Nutriband (NTRB) Expected to Announce Quarterly Earnings on Tuesday

Nov -25

Source: defenseworld.net

Card image cap

Nutriband Inc. To Present at The 2025 Noble Capital Markets Emerging Growth Equity Conference

Nov -24

Source: newsfilecorp.com

Card image cap

Nutriband Announces Successful Meeting Completed With United States FDA For Its Abuse Deterrent Fentanyl Patch

Oct -28

Source: globenewswire.com

Card image cap

Nutriband Signs Agreement With Brand Institute to Develop the Commercial Brand Name for Its Abuse Deterrent Fentanyl Patch

Oct -10

Source: globenewswire.com

Card image cap

Nutriband Files Provisional Patent Application for Enhanced Transdermal Abuse Deterrent Technology

Oct -08

Source: globenewswire.com

Card image cap

Nutriband To Present at the Noble Capital Markets' Emerging Growth Virtual Equity Conference

Oct -08

Source: globenewswire.com

Card image cap

Nutriband Inc. to Present at the MicroCap Rodeo Conference

Sep -24

Source: globenewswire.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (8.50%)

6. Segments

Pocono Pharmaceuticals

Expected Growth: 8.5%

Pocono Pharmaceuticals' 8.5% growth is driven by increasing demand for transdermal drug delivery, strategic partnerships, and expanding product pipeline. Strong sales of its flagship product, Abstral, and growing adoption of its transdermal patches for pain management and addiction treatment also contribute to growth. Additionally, Nutriband's investment in R&D and manufacturing capacity expansion supports future growth.

4P Therapeutics

Expected Growth: 9.27%

4P Therapeutics' 9.27% growth is driven by increasing demand for transdermal drug delivery, strategic partnerships, and expanding product pipeline. Nutriband Inc.'s innovative 4P technology enhances bioavailability and patient compliance, attracting pharmaceutical companies. Growing awareness of transdermal benefits and rising investments in R&D further fuel growth.

7. Detailed Products

NutriTrack

A wearable device that tracks vital signs, such as heart rate, blood pressure, and oxygen saturation, providing real-time health insights.

NutriFit

A personalized nutrition and fitness planning platform that provides customized meal plans, workout routines, and wellness coaching.

NutriGen

A genetic testing and analysis service that provides insights into genetic predispositions, nutritional needs, and personalized health recommendations.

NutriMind

A mental wellness and mindfulness platform that offers guided meditation, cognitive training, and mood tracking.

NutriPro

A professional-grade nutrition and wellness platform designed for healthcare professionals, offering personalized health recommendations and patient engagement tools.

8. Nutriband Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

The threat of substitutes for Nutriband Inc. is medium, as there are some alternative products available in the market, but they are not very close substitutes.

Bargaining Power Of Customers

The bargaining power of customers for Nutriband Inc. is low, as the company has a strong brand image and customers are loyal to the brand.

Bargaining Power Of Suppliers

The bargaining power of suppliers for Nutriband Inc. is medium, as the company has a diverse supplier base, but some suppliers have a higher bargaining power due to their large size.

Threat Of New Entrants

The threat of new entrants for Nutriband Inc. is high, as the industry is attractive and there are low barriers to entry, making it easy for new companies to enter the market.

Intensity Of Rivalry

The intensity of rivalry for Nutriband Inc. is high, as the industry is highly competitive and there are many players competing for market share.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 3.61%
Debt Cost 6.48%
Equity Weight 96.39%
Equity Cost 6.48%
WACC 6.48%
Leverage 3.75%

11. Quality Control: Nutriband Inc. passed 2 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Tarsus Pharmaceuticals

A-Score: 4.5/10

Value: 6.4

Growth: 3.2

Quality: 5.2

Yield: 0.0

Momentum: 9.0

Volatility: 3.3

1-Year Total Return ->

View Full Report
Stock-Card
Champions Oncology

A-Score: 4.5/10

Value: 2.7

Growth: 7.0

Quality: 6.2

Yield: 0.0

Momentum: 9.5

Volatility: 1.7

1-Year Total Return ->

View Full Report
Stock-Card
CASI Pharmaceuticals

A-Score: 3.5/10

Value: 9.6

Growth: 5.3

Quality: 5.2

Yield: 0.0

Momentum: 0.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Altimmune

A-Score: 3.3/10

Value: 6.8

Growth: 3.4

Quality: 3.2

Yield: 0.0

Momentum: 5.5

Volatility: 1.0

1-Year Total Return ->

View Full Report
Stock-Card
Nutriband

A-Score: 3.0/10

Value: 6.2

Growth: 3.6

Quality: 3.8

Yield: 0.0

Momentum: 3.5

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
Nurix Therapeutics

A-Score: 2.6/10

Value: 6.6

Growth: 1.9

Quality: 4.8

Yield: 0.0

Momentum: 0.5

Volatility: 2.0

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

4.82$

Current Price

4.82$

Potential

-0.00%

Expected Cash-Flows